Please login to the form below

Not currently logged in
Email:
Password:

Patients prefer AZ asthma drug

Details of a recent study presented at the International Conference of the American Thoracic Society in Toronto showed that asthma patients prefer AstraZeneca's (AZ) Symbicort to GlaxoSmithKline's (GSK) Adviar.

Details of a recent study presented at the International Conference of the American Thoracic Society in Toronto showed that asthma patients prefer AstraZeneca's (AZ) Symbicort to GlaxoSmithKline's (GSK) Adviar.

Patients involved in the open-label study favoured Symbicort administered as an adjustable dose treatment option as opposed to Advair. The two drugs have a similar mode of action and are competing against each other in the large and lucrative asthma market.

"These data showed that patients treated with Symbicort combination therapy fixed dose were more satisfied with the timelines of their symptom relief than those patients treated with Advair combination," said Dr Richard O'Connor, lead investigator of the study.

Despite being available as an adjustable dose treatment in over 87 countries, Symbicort is not indicated for that use in the US but was launched as a long-term maintenance treatment last year.

GSK reported global sales of Adviar worth $6.4bn in 2007 where as AZ recorded sales worth $1.6bn during the same year.

21st May 2008

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Digitas Health

Digitas Health is the only digital-at-the-core brand agency designed to connect today's healthcare brands with today's healthcare consumers and professionals....

Latest intelligence

ema1
The European Medicines Agency: PRIME’d for access?
Leela Barham examines the impact of the EMA's PRIME fast track system after two years...
How can pharma engage with key stakeholders on NHS service transformation?
Steve How, Paul Midgley and Oli Hudson, of the Wilmington Healthcare consulting team, explain how pharma should make its case for change...
michael elliot
The race for an HIV ‘cure’
Supercharging therapies as pharma and patients work together...

Infographics